Physician profile
Mark M Taylor
NPI 1801869607
$3,514.43
in general payments reported to CMS, 2019-2025
38 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $488 · 2021: $712 · 2022: $687 · 2023: $775 · 2024: $295 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.37 | 2020-2024 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $402.15 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $255.26 | 2019-2023 | |
| Lilly USA, LLC | $254.00 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $166.15 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Medtronic, INC. | $155.75 | 2022-2025 | Hawkone, Sonicision, In.Pact Av |
| Allergan, INC. | $149.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.20 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.92 | 2019-2022 | |
| Amgen INC. | $131.04 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $103.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $73.09 | 2021 | |
| Glaxosmithkline, LLC. | $71.15 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $70.38 | 2019-2023 | Freestyle Libre 3 |
| Lundbeck LLC | $67.44 | 2023-2024 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.